Archived AES Symposia 2005
Resective Epilepsy Surgery - Patient Selection and Outcomes
Program Length: 1 hrs 50 min
Insufficient seizure control with available antiepileptic drugs is unfortunately more common than generally appreciated, reaching an incidence of 40% in certain diagnostic groups. In appropriate circumstances, such patients can be considered for resective surgical treatment, which offers the possibility of seizure cure. Our knowledge of long-term seizure response and its determinants, however, is still evolving. Furthermore, components of outcome encompassing psychiatric status, neurocognitive function, and health-related quality of life are as important as seizure outcome. Yet an appreciation of those effects, their evolution, and their influence on seizures and on one another is just emerging. Advances in our understanding of these results of resective surgical treatment for patients with uncontrolled epilepsy will be presented in the context of approaches to patient selection, long-term management, and patient counseling.
At the conclusion of this activity, participants should be able to:
- Recognize the factors that determine medically refractory epilepsy and contribute to selection of patients for resective epilepsy surgery
- Assess the latest information on seizure response to resective epilepsy surgery, its natural history over time, the prediction of that response, and the influence of other aspects of outcome
- Evaluate how seizure outcome influences postoperative changes in psychiatric and neurocognitive function, and how all these factors affect quality of life
- Identify and discuss areas of continuing uncertainty regarding resective epilepsy surgery
- Manage patient counseling needs before and after resective epilepsy surgery.
Chair: Susan S. Spencer, M.D.
Clinicians who diagnose and treat patients with epilepsy (i.e., neurologists, neurosurgeons, child neurologists, nurses, social workers, psychiatrists, psychologists, and primary care physicians); researchers involved with epilepsy surgery; and pharmacists who work in the clinical neurosciences.
This program and its repurposing on the AES Web site with CME credit is supported by an educational grant from UCB Pharma, Inc.
Disclosure: It is the policy of the American Epilepsy Society that all faculty participating in continuing medical education activities are expected to disclose to the program audience (1) any real or apparent conflict(s) of interest related to the content of their presentation and (2) discussions of unlabeled or unapproved uses of drugs or medical devices. The American Epilepsy Society adheres to the ACCMEs Essential Areas and Policies regarding industry support of continuing medical education. Disclosure by faculty of commercial relationships, if any, and discussions of unlabeled or unapproved uses will be made.
Dr. Spencer has disclosed the following affiliations with commercial supporters of CME: NeuroPace, Inc. Disclosure of Unlabeled/Unapproved Uses Dr. Spencer does not intend to reference unlabeled/unapproved uses of drugs or products in her presentation.
Orrin Devinsky, MD has no real or apparent conflicts of interest to report. Dr. Devinsky does not intend to reference unlabeled/unapproved uses of drugs or products in his presentation.
John T. Langfitt, PhD has no real or apparent conflicts of interest to report. Dr. Langfitt does not intend to reference unlabeled/unapproved uses of drugs or products in his presentation.
Barbara G. Vickrey, MD, MPH has no real or apparent conflicts of interest to report. Dr. Vickrey does not intend to reference unlabeled/unapproved uses of drugs or products in her presentation.
Edward B. Bromfield, MD discloses that he has received consulting fees from UCB Pharma and Cyberonics, that he has received fees for non-CME services from UCB Pharma, Abbott, GlaxoSmithKline and Vovartis and that he has received fees for contracted research from UCB Pharma.
Kay Sloves, Michelle Dien, Rene Hadley and Thomas Schultz have no real or apparent conflicts of interest to report.
Disclaimer: Opinions expressed with regard to unapproved uses of products are solely those of the faculty and are not endorsed by the American Epilepsy Society or any manufacturers of pharmaceuticals.